191 related articles for article (PubMed ID: 35999255)
1. Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients.
Xiong YY; Wang J; Wang L; Chen JB; Liu L; Tang XQ; Wang X; Zhang HB
Sci Rep; 2022 Aug; 12(1):14369. PubMed ID: 35999255
[TBL] [Abstract][Full Text] [Related]
2. [IEAC versus CEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for lymphoma: analysis of efficacy and safety in 106 cases].
Xiong Y; Chen J; Liu L; Luo X; Tang X; Wang X; Xiao Q; Zhang H; Wang L
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Dec; 40(12):1760-1767. PubMed ID: 33380399
[TBL] [Abstract][Full Text] [Related]
3. CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.
Wang T; Liu P; Xu L; Gao L; Ni X; Tang G; Chen L; Chen J; Wang L; Wang Y; Fu W; Yue W; Liu N; Li R; Lu G; Luo Y; Yang J
Ann Hematol; 2024 Feb; 103(2):575-582. PubMed ID: 37932468
[TBL] [Abstract][Full Text] [Related]
4. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
5. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
Liu H; Zou H; Shan D; Liu W; Huang W; Sui W; Deng S; Wang T; Lv R; Fu M; Xu Y; Yi S; An G; Zhao Y; Qiu L; Zou D
Cancer Med; 2024 Jan; 13(2):e6965. PubMed ID: 38348996
[TBL] [Abstract][Full Text] [Related]
8. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Wu R; Ma L
Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
Lin M; Wu X; Zhang L; Li L; Wang X; Fu X; Sun Z; Zhang X; Zhu L; Yu H; Chang Y; Nan F; Yan J; Zhou Z; Shi C; Zhang M; Li X
Leuk Lymphoma; 2023 Mar; 64(3):605-612. PubMed ID: 36657436
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients.
Deveci B; Ateşoğlu EB; Bayrak E; Kublashvili G; Toptaş T; Saba R; Gülbaş Z
Transplant Proc; 2023; 55(1):235-241. PubMed ID: 36639277
[TBL] [Abstract][Full Text] [Related]
12. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
13. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
14. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
[TBL] [Abstract][Full Text] [Related]
15. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.
Colita A; Colita A; Bumbea H; Croitoru A; Orban C; Lipan LE; Craciun OG; Soare D; Ghimici C; Manolache R; Gelatu I; Vladareanu AM; Pasca S; Teodorescu P; Dima D; Lupu A; Coriu D; Tomuleasa C; Tanase A
Front Oncol; 2019; 9():892. PubMed ID: 31552193
[TBL] [Abstract][Full Text] [Related]
16. Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning.
Vely A; Paillassa J; Nunes Gomes C; Giltat A; Fouquet S; Lebreton A; Klemencie M; Clavert A; Tanguy-Schmidt A; Hunault-Berger M; Orvain C
Ann Hematol; 2023 Aug; 102(8):2225-2231. PubMed ID: 37380715
[TBL] [Abstract][Full Text] [Related]
17. Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.
Tian C; Li Y; Liu S; Chen Z; Zhang Y; Yu Y; Yang H; Zhao H; Zhao Z; Yuan T; Wang Y
Sci Rep; 2021 Feb; 11(1):4273. PubMed ID: 33608570
[TBL] [Abstract][Full Text] [Related]
18. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
20. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
